<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy/Pharmacies/Compounding.html">
<title>Compounding RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy/Pharmacies/Compounding.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-07-04T13:00+51:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Compounding RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156435.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156423.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156424.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156429.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156431.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156432.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156297.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156266.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156267.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156271.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156264.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156265.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156152.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156158.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156116.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156138.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156084.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156085.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155919.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155914.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155916.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155917.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155861.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155862.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155823.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156330.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156271.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156244.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156256.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156183.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156159.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156116.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155978.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155851.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155804.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155806.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155693.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155694.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155661.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155585.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155452.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155345.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155347.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155361.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155376.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155340.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155343.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155173.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155126.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155040.php" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170276.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170100.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169853.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169733.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169862.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169471.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169656.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169093.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169369.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168870.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168583.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168574.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168084.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167908.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167880.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167187.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167065.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167435.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167410.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm166801.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170458.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170457.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170448.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170447.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170229.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170154.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm169408.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm169161.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm168763.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm144133.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm167989.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm167954.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm167654.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm170044.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm167139.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm166366.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm165984.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm166719.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm166346.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm165618.htm" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.medicalnewstoday.com/articles/156435.php">
<title>Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)</title>
<link>http://www.medicalnewstoday.com/articles/156435.php</link>
<description><![CDATA[Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156423.php">
<title>BioCis Pharma Reports Positive Phase IIa Clinical Results In Atopic Dermatitis</title>
<link>http://www.medicalnewstoday.com/articles/156423.php</link>
<description><![CDATA[BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156424.php">
<title>ThromboGenics And BioInvent Start Recruitment Of Second 100 Patient Cohort In Phase II DVT Prophylaxis Study With TB-402</title>
<link>http://www.medicalnewstoday.com/articles/156424.php</link>
<description><![CDATA[ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156429.php">
<title>First Ten-Year Follow-Up Shows That Treatment With AVONEX&#xAE; Leads To Long-Term Benefits In Early Multiple Sclerosis Patients</title>
<link>http://www.medicalnewstoday.com/articles/156429.php</link>
<description><![CDATA[Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study).  Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156431.php">
<title>ONGLYZA&#x2122; (Saxagliptin) Receives Positive Opinion In Europe For The Treatment Of Type 2 Diabetes</title>
<link>http://www.medicalnewstoday.com/articles/156431.php</link>
<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156432.php">
<title>Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion</title>
<link>http://www.medicalnewstoday.com/articles/156432.php</link>
<description><![CDATA[Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156297.php">
<title>WHO, Wyeth Launch Trial In Africa To Test New River Blindness Drug</title>
<link>http://www.medicalnewstoday.com/articles/156297.php</link>
<description><![CDATA[The WHO on Wednesday announced plans for a clinical trial to test a new drug that "could halve the treatment period for river blindness [or onchocerciasis], a disease that threatens 100 million people mostly in Africa," AFP/Dow Jones Newswires/CNN Money reports (7/1).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156266.php">
<title>FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter</title>
<link>http://www.medicalnewstoday.com/articles/156266.php</link>
<description><![CDATA[Sanofi-aventis (EURONEXT: SAN and NYSE:  SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156267.php">
<title>Spanish Government Selects Novavax&#x27;s VLP Technology For Comprehensive Flu Vaccine Solution In Spain</title>
<link>http://www.medicalnewstoday.com/articles/156267.php</link>
<description><![CDATA[Novavax, Inc. (Nasdaq:  NVAX) announced its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156271.php">
<title>Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value</title>
<link>http://www.medicalnewstoday.com/articles/156271.php</link>
<description><![CDATA[Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows:    1.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156264.php">
<title>Lixte Biotechnology Holdings&#x27; Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherapy In Animal Models</title>
<link>http://www.medicalnewstoday.com/articles/156264.php</link>
<description><![CDATA[Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156265.php">
<title>Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)</title>
<link>http://www.medicalnewstoday.com/articles/156265.php</link>
<description><![CDATA[Acura Pharmaceuticals, Inc. (Nasdaq:  ACUR) and King Pharmaceuticals, Inc. (NYSE:  KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain.         The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156152.php">
<title>Questions Linger Over Pharmaceutical Deal Agreement To Cut Costs</title>
<link>http://www.medicalnewstoday.com/articles/156152.php</link>
<description><![CDATA[ "As details emerge of the pharmaceutical industry's agreement to kick in $80 billion to help pay for health care reform, the deal is facing increasing skepticism from inside and outside the health care industry," Politico reports.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156158.php">
<title>Drug Industry Increases Lobbying Efforts And Targets Democrats</title>
<link>http://www.medicalnewstoday.com/articles/156158.php</link>
<description><![CDATA[The drug industry began ramping up its lobbying efforts in 2003, when Medicare Part D began, and now is targeting Democrats.                 CQ Politics reports: "The industry is increasingly employing Democratic lobbyists with ties to the Obama administration and congressional leaders such as Sen. Max Baucus, D-Mont., chairman of the Senate Finance Committee.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156116.php">
<title>Potential New Drugs: 970 Million And Still Counting - Journal Of The American Chemical Society</title>
<link>http://www.medicalnewstoday.com/articles/156116.php</link>
<description><![CDATA[Like astronomers counting stars in the familiar universe of outer space, chemists in Switzerland are reporting the latest results of a survey of chemical space - the so-called chemical universe where tomorrow's miracle drugs may reside. The scientists conclude, based on this phase of the ongoing count, that there are 970 million chemicals suitable for study as new drugs.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156138.php">
<title>Roche To Offer Developing Countries Discounted Tamiflu</title>
<link>http://www.medicalnewstoday.com/articles/156138.php</link>
<description><![CDATA[The pharmaceutical company Roche on Wednesday announced a program to help ensure developing countries have access to its antiviral Tamiflu, for "the management of a novel influenza strain defined by the WHO as having significant and current pandemic potential," Reuters reports (Egenter, 7/1).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156084.php">
<title>DeCODE-led Megastudy Finds New Genetic Clues To Causes Of Schizophrenia</title>
<link>http://www.medicalnewstoday.com/articles/156084.php</link>
<description><![CDATA[The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational consortium of scientists led by a team from deCODE genetics (Nasdaq: DCGN), analyzed the genomes of more than 50,000 patients and control participants from fourteen countries. It is published today in the online edition of Nature.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156085.php">
<title>Peregrine Awarded European Patent For Innovative Labeling Technology Featured In New Study In The Journal Of Nuclear Medicine</title>
<link>http://www.medicalnewstoday.com/articles/156085.php</link>
<description><![CDATA[Peregrine Pharmaceuticals, Inc. (Nasdaq:  PPHM) today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable to other agents as well.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155919.php">
<title>Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections</title>
<link>http://www.medicalnewstoday.com/articles/155919.php</link>
<description><![CDATA[Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155914.php">
<title>Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The Treatment Of Respiratory Diseases</title>
<link>http://www.medicalnewstoday.com/articles/155914.php</link>
<description><![CDATA[Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.    The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155916.php">
<title>PROLOR Biotech Awarded Two U.S. Patents For Its Longer-Acting Human Growth Hormone And Longer-Acting Erythropoietin</title>
<link>http://www.medicalnewstoday.com/articles/155916.php</link>
<description><![CDATA[PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., announced that the U. S. Patent and Trademark Office (PTO) has issued two new patents for the company's long-acting CTP-enhanced human growth hormone (hGH-CTP) and human erythropoietin (EPO-CTP). The patents cover the composition of PROLOR's proprietary pharmaceutical compounds as well as certain associated methods.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155917.php">
<title>Cephalon Submits NUVIGIL Supplemental New Drug Application For The Treatment Of Excessive Sleepiness Associated With Jet Lag Disorder</title>
<link>http://www.medicalnewstoday.com/articles/155917.php</link>
<description><![CDATA[Cephalon, Inc. (Nasdaq:  CEPH) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155861.php">
<title>Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict From Abbott Laboratories</title>
<link>http://www.medicalnewstoday.com/articles/155861.php</link>
<description><![CDATA[Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit.    "We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott," said Kim Taylor, President, Centocor Ortho Biotech Inc.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155862.php">
<title>Baxter To Acquire Continuous Renal Replacement Therapy Business From Edwards Lifesciences</title>
<link>http://www.medicalnewstoday.com/articles/155862.php</link>
<description><![CDATA[Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards' hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155823.php">
<title>Vietnamese Drug Authority Teams With United States Standards-Setting Organization</title>
<link>http://www.medicalnewstoday.com/articles/155823.php</link>
<description><![CDATA[As Vietnam's industrial capabilities have developed rapidly in recent decades, government officials have recognized the importance of helping to secure the nation's supply of medicines. In an important milestone addressing this need, the Vietnamese Pharmacopoeia Commission (VPC) has signed a memorandum of understanding (MOU) with the U.S. Pharmacopeial (USP) Convention.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156330.php">
<title>A Selection Of Recent Studies And Surveys</title>
<link>http://www.medicalnewstoday.com/articles/156330.php</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156271.php">
<title>Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value</title>
<link>http://www.medicalnewstoday.com/articles/156271.php</link>
<description><![CDATA[Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows:    1.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156244.php">
<title>Impact Of Medicare Part D On Medical Spending Addressed By NEJM Study</title>
<link>http://www.medicalnewstoday.com/articles/156244.php</link>
<description><![CDATA[After enrolling in Medicare Part D, seniors who previously had limited or no drug coverage spent more on prescriptions and less on other medical care services such as hospitalizations and visits to the doctor's office, according to a University of Pittsburgh Graduate School of Public Health study.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156256.php">
<title>FDA Panel Votes To Restrict Acetaminophen</title>
<link>http://www.medicalnewstoday.com/articles/156256.php</link>
<description><![CDATA[An advisory committee to the US Food and Drug Administration (FDA) voted on Tuesday to recommend new restrictions on the popular pain     relief drug acetaminophen (known in many other countries as paracetamol), which is found in many US top selling over the counter medications such     as Tylenol, aspirin-free Anacin, Excedrin, and also in prescription drugs such as Vicodin and Percocet.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156183.php">
<title>Closer Working Between GPs And Community Pharmacists Would Save Lives And Improve NHS Cost Effectiveness And Care Quality</title>
<link>http://www.medicalnewstoday.com/articles/156183.php</link>
<description><![CDATA[The NHS Chief Executive has recently warned that the NHS could have to   make 'unprecedented' efficiency savings of up to Â£20 billion between 2011 and   2014. David Nicholson's Annual Report1 also emphasised that services should   where possible move out of hospital to primary care and into the community, to   allow both better quality and improved productivity.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156159.php">
<title>Pharmacies Urged To Register From  1 - 31 July 2009 To Receive Early-bird Payment</title>
<link>http://www.medicalnewstoday.com/articles/156159.php</link>
<description><![CDATA[Community pharmacies are urged to register to participate in Phase 2 of the Dose Administration Aids   (DAA) and Patient Medication Profile (PMP) programs.       Pharmacies registering from 1 to 31 July 2009 will be eligible for the full incentive payment of $2,250 for   DAA and $1,250 for PMP (+GST). While registrations will still be accepted after July, a lesser incentive   payment will apply.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156116.php">
<title>Potential New Drugs: 970 Million And Still Counting - Journal Of The American Chemical Society</title>
<link>http://www.medicalnewstoday.com/articles/156116.php</link>
<description><![CDATA[Like astronomers counting stars in the familiar universe of outer space, chemists in Switzerland are reporting the latest results of a survey of chemical space - the so-called chemical universe where tomorrow's miracle drugs may reside. The scientists conclude, based on this phase of the ongoing count, that there are 970 million chemicals suitable for study as new drugs.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155978.php">
<title>Today&#x27;s Selection Of Opinions And Editorials</title>
<link>http://www.medicalnewstoday.com/articles/155978.php</link>
<description><![CDATA[					  		        ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155851.php">
<title>Chair Of General Pharmaceutical Council Is Welcomed By Society</title>
<link>http://www.medicalnewstoday.com/articles/155851.php</link>
<description><![CDATA[The Royal Pharmaceutical Society of Great Britain (RPSGB) has welcomed the appointment of Mr Robert Nicholls CBE as the Chair Designate of the General Pharmaceutical Council (GPhC).   The GPhC will be the new regulator for Great Britain's pharmacists, pharmacy technicians and pharmacy premises in 2010. His appointment is another key stage in its establishment.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155804.php">
<title>NACDS, NCPA Endorse Rep. Mike Ross&#x27; Medication Therapy Management Legislation</title>
<link>http://www.medicalnewstoday.com/articles/155804.php</link>
<description><![CDATA[Today, the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) announced their support for H.R. 3108, the Medication Therapy Management Benefits Act of 2009,  sponsored by Rep. Mike Ross (D-AR).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155806.php">
<title>NACDS Retail Advisory Board Explores Social Networking Opportunities To Engage Consumers</title>
<link>http://www.medicalnewstoday.com/articles/155806.php</link>
<description><![CDATA[ The Retail Advisory Board (RAB) of the National Association of Chain Drug Stores (NACDS) met yesterday during the 2009 NACDS Marketplace Conference to discuss social networking opportunities within their businesses.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155693.php">
<title>The Countdown Starts For Pharmacy Technician Registration</title>
<link>http://www.medicalnewstoday.com/articles/155693.php</link>
<description><![CDATA[Pharmacy technicians throughout England, Scotland and Wales will be regulated by the Royal   Pharmaceutical Society of Great Britain on a statutory basis for the first time when legislation   comes into force on 1 July.         The new regulations are a positive step for pharmacy technicians, reflecting the growing role   and responsibility they have as healthcare professionals.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155694.php">
<title>Pharmacy Preregistration Training Reviewed In First National Survey</title>
<link>http://www.medicalnewstoday.com/articles/155694.php</link>
<description><![CDATA[Preregistration trainees and tutors in England, Scotland and Wales will be asked to take part in   the first ever national pilot survey on pharmacy preregistration training standards, this summer.     The project is a collaboration between the Royal Pharmaceutical Society of Great Britain  (RPSGB) and the University of Keele.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155661.php">
<title>Trust&#x27;s Antibiotic Guidelines Given National Credit, UK</title>
<link>http://www.medicalnewstoday.com/articles/155661.php</link>
<description><![CDATA[Southampton's teaching hospitals have been recognised by one of the UK's top medical organisations for leading the way in use of antibiotics in the fight against infection. The British Medical Association, the professional body for doctors and medical students, praised Southampton University Hospitals NHS Trust's development of clear and simple antimicrobial prescribing guidelines for staff.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155585.php">
<title>Auburn Pharmacy School Helps Design High-Tech Home Health Pharmacy</title>
<link>http://www.medicalnewstoday.com/articles/155585.php</link>
<description><![CDATA[A new Auburn University-designed, high-tech pharmacy in Meridian, Miss., is the first of its kind and is a model facility that could be built in communities across the United States.    Auburn pharmacy professors Kenneth Barker and Betsy Flynn led a multidisciplinary team in designing the recently opened facility for Vital Care Inc., which will help pharmacists offer complex medications for in-home use, ones that are normally administered only in hospitals.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155452.php">
<title>NCPA To Congress: Health Reform Should Empower Community Pharmacies To Improve Patient Outcomes, Reduce Costs</title>
<link>http://www.medicalnewstoday.com/articles/155452.php</link>
<description><![CDATA[National Community Pharmacists Association (NCPA) Executive Vice President and CEO, Bruce T. Roberts, RPh testified today before the U.S. House Energy and Commerce Subcommittee on Health, offering four different recommendations to strengthen a health care reform proposal currently working its way through Congress.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155345.php">
<title>Healthcare Reform Expert And Former Senate Majority Leader Tom Daschle To Address NACDS Pharmacy &#x26; Technology Conference</title>
<link>http://www.medicalnewstoday.com/articles/155345.php</link>
<description><![CDATA[The National Association of Chain Drug Stores (NACDS) announced former U.S. Senate Majority Leader Tom Daschle (D-SD) as this year's keynote speaker at the NACDS Pharmacy and Technology Conference.  Senator Daschle will speak on Sunday, August 9, 2009, at the Business Program to be held from 8:00 to 9:30 a.m.    "Senator Daschle is a healthcare expert," commented NACDS President and CEO Steven C. Anderson, IOM, CAE.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155347.php">
<title>NACDS To Honor Len DeMino At NACDS Pharmacy &#x26; Technology Conference As Industry Icon Announces Retirement As Consultant To The Association</title>
<link>http://www.medicalnewstoday.com/articles/155347.php</link>
<description><![CDATA[  The National Association of Chain Drug Stores (NACDS) today announced that the 2009 NACDS Pharmacy & Technology Conference will provide a forum at which to provide further recognition to Leonard J. DeMino, RPh., a chain pharmacy icon whose resume already includes some of the industry's highest honors and achievements.  This news comes as DeMino announces his retirement as senior pharmacy consultant to NACDS, effective in June 2009.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155361.php">
<title>FDA Approves Generic Prescription-Only Version Of Plan B Emergency Contraceptive For Women Ages 17 And Under</title>
<link>http://www.medicalnewstoday.com/articles/155361.php</link>
<description><![CDATA[The U.S. Food and Drug Administration approved the first generic version of the emergency contraceptive Plan B (levonorgestrel) tablets, 0.75 mg. The generic product will be available by prescription only for women ages 17 and under.    Plan B was first approved in 1999 for prescription use only for women of all ages. Plan B is manufactured by Duramed Pharmaceuticals Inc., of Cincinnati.   In 2006, Plan B was approved for nonprescription use for women ages 18 and older.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155376.php">
<title>DrugScope: NTA Naloxone Pilot Scheme Can Help Reduce Drug-related Deaths, UK</title>
<link>http://www.medicalnewstoday.com/articles/155376.php</link>
<description><![CDATA[DrugScope has today welcomed the National Treatment Agency's announcement of a pilot scheme that will see families and carers of opiate users trained in drug overdose management and the administration of naloxone, a drug which reverses the effects of a drug overdose [1].   Naloxone is an opioid antagonist which blocks the effects of opiates, such as heroin or methadone.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155340.php">
<title>Time To Consider Expanding Prescribing Rights</title>
<link>http://www.medicalnewstoday.com/articles/155340.php</link>
<description><![CDATA[Governments and health professionals across Australia need to give full and detailed   consideration to granting pharmacists and other non-medial health professionals the right to   prescribe medications, the Pharmaceutical Society of Australia says.       President of the PSA, Warwick Plunkett, said today that some non-medical health   professions have already been granted prescribing rights and it was time that this right was   also granted to pharmacists.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155343.php">
<title>Nominations Sought For PSA Awards For Excellence</title>
<link>http://www.medicalnewstoday.com/articles/155343.php</link>
<description><![CDATA[Nominations for the prestigious 2009 Pharmaceutical Society of Australia Awards for   Excellence are being called for with winners to be announced at the Pharmacy Congress   Australia in October.   The PSA's Pharmacist of the Year, Young Pharmacist of the Year and Lifetime Recognition   Awards are regarded in the profession as pinnacles of achievement and are held in the   highest esteem both within and outside the profession.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155173.php">
<title>IFPMA Announces Johnson &#x26; Johnson As New Member Company</title>
<link>http://www.medicalnewstoday.com/articles/155173.php</link>
<description><![CDATA[The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Johnson & Johnson has become its newest member company.     IFPMA Acting Director General Michael D. Boyd said: "Johnson & Johnson is an important company in our industry and one which is particularly active in working to help improve health in developing countries.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155126.php">
<title>Kohl Bill Would Save Consumers $3.5 Billion Per Year, According To FTC, USA</title>
<link>http://www.medicalnewstoday.com/articles/155126.php</link>
<description><![CDATA[ U.S. Senator Herb Kohl released the following statement on the announcement from U.S. Federal Trade Commission Chairman Jon Leibowitz that banning pay-for-delay settlements that keep generic drugs off the market would save consumers at least $3.5 billion per year and provide significant cost savings for federal government, which pays approximately one-third of all prescription drug costs.  Senator Kohl's bill, the Preserve Access to Affordable Generic Drugs Act (S.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155040.php">
<title>International Society For Pharmaceutical Engineering Asks Pharma Professionals To Share Their Knowledge</title>
<link>http://www.medicalnewstoday.com/articles/155040.php</link>
<description><![CDATA[ ISPE, a global not-for-profit association of 25,000 pharmaceutical science and manufacturing professionals, announced that it is accepting proposals from pharmaceutical professionals for content that can be included in a variety of its educational resources.     "As a membership organization, ISPE truly relies on the contributions of dedicated and altruistic pharmaceutical professionals to advance their industry," said Robert P. Best, ISPE President and CEO.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170276.htm">
<title>FDA Approves Multaq to Treat Heart Rhythm Disorder</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170276.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170100.htm">
<title>FDA: Boxed Warning on Serious Mental Health Events to be Required for Chantix and Zyban</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170100.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169853.htm">
<title>FDA Seeks Public Input on Tobacco Regulation</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169853.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration announced today that it is seeking public input on the implementation of its historic new authority overseeing tobacco products in the United States. In a Federal Register notice, the agency invites the public to provide information and share views on a wide range of topics, from product content to advertising and marketing.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169733.htm">
<title>FDA Confirms E. Coli O157:H7 in Prepackaged Nestl&#xE9; Toll House Refrigerated Cookie Dough</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169733.htm</link>
<description><![CDATA[Today, the U.S. Food and Drug Administration announced that it has found E. coli O157:H7 (a bacterium that can cause serious food borne illness) in a sample of prepackaged Nestlé Toll House refrigerated cookie dough currently under recall by the manufacturer and marketer, Nestlé USA.  The contaminated sample was collected at Nestlé’s facility in Danville, Va. on June 25, 2009.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169862.htm">
<title>U.S. Attorney News Release: Ringleader Sentenced to Nine Years In Federal Prison For Allergy Testing Health Care Fraud Scheme That Bilked Insurance Companies and Deceived Thousands of Patients</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169862.htm</link>
<description><![CDATA[A registered nurse who directed an allergy testing health care fraud scheme, was sentenced to nine years in prison and ordered to pay $2.6 million in restitution, federal law enforcement officials announced today. John Froelich, 52, formerly of Harwood Heights, was the ringleader among nine defendants who pleaded guilty to federal charges for submitting fraudulent bills totaling $11.5 million to more than 200 insurance companies, which paid approximately $2.6 million in false claims.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169471.htm">
<title>Company Recalls Various Products Due to Potential Salmonella Contamination</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169471.htm</link>
<description><![CDATA[FDA, USDA, CDC investigating; no link to human illnesses at this time.  Plainview Milk Products Cooperative, Plainview, Minn., is voluntarily recalling all instant nonfat dried milk, whey protein, fruit stabilizers, and gums (thickening agents) that it has manufactured over the past two years, because they might be contaminated with Salmonella.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169656.htm">
<title>U.S. Attorney Press Release:  Scottsdale Man Pleads Guilty to Multiple Federal Charges Related to Marketing  of Sexual Enhancement Drug</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169656.htm</link>
<description><![CDATA[Timothy Keay Isaac, 47, of Scottsdale, Ariz., pleaded guilty earlier this week
to Conspiracy, Introducing Misbranded Drugs into Interstate Commerce, Making False Tax
Returns, Filing False Declarations in a Bankruptcy Proceeding and Theft of Government Money.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169093.htm">
<title>U.S. Marshals Seize Drug Products Manufactured by Caraco Pharmaceutical Laboratories Ltd.</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169093.htm</link>
<description><![CDATA[U.S. Marshals Seize Drug Products Manufactured by Caraco Pharmaceutical Laboratories Ltd.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169369.htm">
<title>U.S. Attorney News Release: Former Managing Pharmacist Pleads Guilty To Conspiracy to Defraud Health Insurers</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm169369.htm</link>
<description><![CDATA[The former managing pharmacist at a Middlesex County pharmacy pleaded
guilty today to conspiring to defraud health insurers, including the federal Medicaid
program, by submitting phony claims for reimbursement for prescription drugs, Acting
U.S. Attorney Ralph J. Marra, Jr., announced.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168870.htm">
<title>FDA Approves Generic Prescription-Only Version of Plan B Emergency Contraceptive for Women Ages 17 and Under</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168870.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today approved the first generic version of the emergency contraceptive Plan B (levonorgestrel) tablets, 0.75 mg. The generic product will be available by prescription only for women ages 17 and under.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168583.htm">
<title>FDA Seeks Public Input on Transparency</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168583.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration will host a daylong meeting on June 24, 2009. During this meeting, the FDA will seek recommendations on how to make information on FDA activities and decision-making useful, understandable, and more accessible to the public. The meeting is scheduled for 8 a.m. to 5 p.m. EDT at the National Transportation Safety Board Conference Center, 429 L’Enfant Plaza, S.W., Washington, D.C., 20594.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168574.htm">
<title>FDA Warns Consumers Not to Eat California Prime Produce and Orange County Orchards Brands of Pistachios</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168574.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is warning consumers not to eat California Prime Produce and Orange County Orchards brands of pistachios repacked by Orca Distribution West Inc., Anaheim, Calif. Orca received and repacked pistachios recalled by Setton Pistachio of Terra Bella Inc., Terra Bella, Calif.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168084.htm">
<title>U.S. Attorney News Release: Howard County Pharmacy Owner Indicted for Health Care Fraud</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm168084.htm</link>
<description><![CDATA[A federal grand jury yesterday indicted Pamela Arrey, age 48, Glenelg, Maryland, for health care fraud and aggravated identity theft, announced United States Attorney for District of Maryland Rod R. Rosenstein]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167908.htm">
<title>FDA Warns Consumers Not to Eat Nestle Toll House Prepackaged, Refrigerated Cookie Dough</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167908.htm</link>
<description><![CDATA[The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are warning consumers not to eat any varieties of Nestle Toll House Refrigerated cookie dough due to the risk of contamination with E. coli O157:H7 (a bacterium that causes food borne illness).]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167880.htm">
<title>U.S. Attorney News Release: Pharmaceutical Company Manager Sentenced for Off-Label Marketing</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167880.htm</link>
<description><![CDATA[BOSTON, MA - A Branchburg, NJ, woman was sentenced today for violating the Food, Drug and Cosmetic Act, for marketing the drug Bextra for uses and dosages that were not approved by the Food and Drug Administration.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167187.htm">
<title>FDA Taking Steps to Improve Contact Lens Safety</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167187.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is taking steps to improve contact lens safety by reminding consumers of the importance of following proper cleaning and storing procedures. Consumers who do not follow instructions for contact lens care and use increase their risk of serious eye infections that can lead to blindness.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167065.htm">
<title>FDA Advises Consumers Not To Use Certain Zicam Cold Remedies</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167065.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today advised consumers to stop using three products marketed over-the-counter as cold remedies because they are associated with the loss of sense of smell (anosmia). Anosmia may be long-lasting or permanent.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167435.htm">
<title>U.S. Attorney News Release: International Medical Device Maker and Four Executives Charged in Connection with Unlawful Clinical Trials</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167435.htm</link>
<description><![CDATA[U.S. Attorney news release]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167410.htm">
<title>U.S. Attorney News Release: Business Owners Plead Guilty to Distributing Tainted Ingredient Used in Pet Food</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm167410.htm</link>
<description><![CDATA[KANSAS CITY, Mo. – Matt J. Whitworth, Acting United States Attorney for the Western District of Missouri, announced that a Nevada company and its owners pleaded guilty in federal court today to distributing a tainted ingredient used to make pet food, which resulted in a nationwide recall of pet food and the death and serious illness of countless pets across the United States in 2007.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm166801.htm">
<title>FDA Warns Web Sites against Marketing Fraudulent H1N1 Flu Virus Claims</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm166801.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is enforcing the laws that protect consumers from illegal products marketed through the Internet that claim to diagnose, prevent, mitigate, treat or cure the 2009 H1N1 flu virus.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170458.htm">
<title>Precision Foods Inc. Recalls Madagascar Vanilla Cocoa Because of Possible Health Risk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170458.htm</link>
<description><![CDATA[Precision Foods Inc., of St. Louis, Missouri, is recalling certain Madagascar Vanilla cocoa as a precaution given that the potential exists that the product may be contaminated with Salmonella.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170457.htm">
<title>Meijer Announces Voluntary Recall of Some Meijer Brand Instant Non-fat Dry Milk Citing Possible Health Risk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170457.htm</link>
<description><![CDATA[Meijer has initiated a voluntary recall of one type of its Meijer Brand Instant Non-fat Dry Milk because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170448.htm">
<title>CPI Foods, Inc Recalls Non Fat Dry Milk Because of Possible Health Risk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170448.htm</link>
<description><![CDATA[CPI Foods, Inc of Dallas, TX is recalling approximately 15,000 (net wt. 20g) packets of non fat dry milk because they have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170447.htm">
<title>NOW Foods Issues Nationwide Voluntary Recall of Whey Protein Concentrate</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170447.htm</link>
<description><![CDATA[NOW Foods has issued a voluntary recall for NOW Foods products containing whey protein concentrate due to potential Salmonella contamination.  This is an extension of the voluntary recall being conducted by the company’s supplier Plainview Milk Products Cooperative.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170229.htm">
<title>Stop &#x26; Shop Issues A Voluntary Recall of Stop &#x26; Shop Non Fat Dry Milk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170229.htm</link>
<description><![CDATA[Following notification from its manufacturer, The Stop & Shop Supermarket Company has recalled the following Stop & Shop Non Fat Dry Milk products...]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170154.htm">
<title>North Coast Seafood is recalling Fresh Tuna Steaks sold in Retail Store in New England</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170154.htm</link>
<description><![CDATA[North Coast Seafood has voluntarily removed from sale Fresh Tuna Steaks that were sold at Shaw’s, Star Market and Big Y Stores in New England]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm169408.htm">
<title>City Baking Brand Apple Crumb Cake</title>
<link>http://www.fda.gov/Safety/Recalls/ucm169408.htm</link>
<description><![CDATA[City Baking LLC, of Long island City, NY is recalling 781 individually wrapped City Baking brand Apple Crumb Cakes, because they contain Walnuts, which were inadvertently omitted from the label.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm169161.htm">
<title>Nuts For You Recalls Roasted &#x26; Salted Peanuts Because of Possible Health Risk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm169161.htm</link>
<description><![CDATA[Nuts For You of Preston, ID is recalling up to 30 lbs of Roasted and Salted Peanuts because they have the potential to be contaminated with Salmonella]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm168763.htm">
<title>La Mexicana, Inc. Issues Allergy Alert on Undeclared Milk and Milk Products in Tortilla Chips</title>
<link>http://www.fda.gov/Safety/Recalls/ucm168763.htm</link>
<description><![CDATA[La Mexicana, Inc., of Seattle, Washington, is recalling Solena Tortilla Chips with a June 03, 2009 code date, because they may contain undeclared milk and milk products]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm144133.htm">
<title>Premier Nutrition Announces Precautionary, Voluntary Nationwide Recall of selected ODYSSEY Branded Bars Containing Peanuts Due to Possible Health Risk</title>
<link>http://www.fda.gov/Safety/Recalls/ucm144133.htm</link>
<description><![CDATA[Premier Nutrition Announces Precautionary, Voluntary Nationwide Recall of selected ODYSSEY Branded Bars Containing Peanuts Due to Possible Health Risk]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm167989.htm">
<title>Unilever United States, Inc. Conducts Nationwide Voluntary Recall of Imported Knorr&#xAE; Kosher Soup Mix - Chicken Vegetable Flavor with Pasta Due to Undeclared Allergen</title>
<link>http://www.fda.gov/Safety/Recalls/ucm167989.htm</link>
<description><![CDATA[Unilever United States, Inc. is voluntarily recalling Knorr® Kosher Soup Mix – Chicken Vegetable Flavor with Pasta imported from Israel because it contains undeclared egg...]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm167954.htm">
<title>Nestl&#xE9; USA&#x2019;s Baking Division Initiates Voluntary Recall</title>
<link>http://www.fda.gov/Safety/Recalls/ucm167954.htm</link>
<description><![CDATA[Nestlé USA’s Baking Division is initiating a voluntary recall of Nestlé® TOLL HOUSE® refrigerated cookie dough products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm167654.htm">
<title>Smith Dairy Announces Voluntary Recall on SMITH&#x27;S Tea with Lemon in Gallon Size Only</title>
<link>http://www.fda.gov/Safety/Recalls/ucm167654.htm</link>
<description><![CDATA[Smith Dairy Products Company today announced a voluntary recall on SMITH’S Tea with Lemon in gallon size, lot no. 07/07/09]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm170044.htm">
<title>Hy-Vee Inc. Recalls Mislabeled Salad Dressing</title>
<link>http://www.fda.gov/Safety/Recalls/ucm170044.htm</link>
<description><![CDATA[Hy-Vee Inc. is voluntarily recalling some 12-oz. bottles of Hy-Vee HealthMarket Organic Balsamic Vinaigrette dressing.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm167139.htm">
<title>Hi-Tech Pharmaceuticals, Inc. Issues Nationwide Recall of All Lots of Stamina-Rx Dietary Supplement Products</title>
<link>http://www.fda.gov/Safety/Recalls/ucm167139.htm</link>
<description><![CDATA[June 15, 2009 - Norcross, GA - Hi-Tech Pharmaceuticals, Inc. (“Hi-Tech”), 6015-B Unity Dr., Norcross, GA 30071, announced today that it is conducting a nationwide voluntary recall of the company's product sold under the name Stamina-Rx.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm166366.htm">
<title>Torres Hillsdale Country Cheese LLC Announces the Recall of all lots of Soft Mexican Cheeses due to Possible Listeria Contamination</title>
<link>http://www.fda.gov/Safety/Recalls/ucm166366.htm</link>
<description><![CDATA[Torres Hillsdale Country Cheese of Reading, Michigan announces the recall of all lots of various types of soft Mexican-style cheeses due to potential Listeria contamination.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm165984.htm">
<title>R. E. Kimball. and Company, Inc. Issues Allergy Alert on Undeclared Milk and Wheat in Clam Chowder and Corn Chowder</title>
<link>http://www.fda.gov/Safety/Recalls/ucm165984.htm</link>
<description><![CDATA[R. E. Kimball and Company, Inc. of Amesbury, MA is voluntarily recalling all approximately 1200 units of Clam Chowder and Corn Chowder, all lot numbers in 15 oz cans, because they contain undeclared Milk and Wheat...]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm166719.htm">
<title>Knouse Foods, Inc. Announces Recall of Apple Sauce in Glass Jars</title>
<link>http://www.fda.gov/Safety/Recalls/ucm166719.htm</link>
<description><![CDATA[June 11, 2009 - Peach Glen, PA - Knouse Foods, Inc. announced today that effective immediately, they have decided to voluntarily recall apple sauce (23.5 and 25 oz glass jars only) with the following Best By Dates for these specific UPC Codes.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm166346.htm">
<title>FoodScience Corporation Recalls Kid&#x2019;s Multivitamin for label Error</title>
<link>http://www.fda.gov/Safety/Recalls/ucm166346.htm</link>
<description><![CDATA[FoodScience Corporation of Essex Junction, Vermont 05452 is voluntarily recalling a total of approximately 1,250 bottles of its Children’s Multi Vitamins...]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm165618.htm">
<title>Indian  Groceries &#x26; Spices, Inc. Issues Allergy Alert on Undeclared Sulfites in Nirav Golden Raisins</title>
<link>http://www.fda.gov/Safety/Recalls/ucm165618.htm</link>
<description><![CDATA[Indian Groceries & Spices, Inc. of Skokie, IL is recalling Nirav Golden Raisins because it may contain undeclared sulfites.]]></description>
</item>

</rdf:RDF>